Keymed Biosciences Announces Interim Results for First Half of 2024

Keymed Biosciences Announces Safety and Efficacy Results of CM313 for Primary Immune Thrombocytopenia Published in NEJM

Keymed Biosciences Announces Long-term Efficacy and Safety Data from a Phase III Clinical Trial of Stapokibart for the Treatment of Moderate-to-severe Atopic Dermatitis

Keymed Biosciences Announces 2023 Annual Results and Business Updates

Keymed Biosciences and Rona Therapeutics Announce Collaboration to Discover and Develop First-in-class siRNA Therapeutics for Glomerulonephritis

Keymed Biosciences Announces 2022 Annual Results